LL-37 Benefits: Biofilm Breaker + 9 Immune Effects (2026)

Wound Healing

LL-37 is naturally upregulated at wound sites, where it orchestrates multiple aspects of the healing process.

Angiogenesis

Preclinical work has reported that LL-37 promotes new blood vessel formation, a key step in wound healing — proposed mechanisms include activation of formyl peptide receptor-like 1 (FPRL1) on endothelial cells. The translational relevance to subcutaneous dosing in humans is unknown.

Epithelial Repair

LL-37 has been reported to stimulate keratinocyte migration and wound re-epithelialization through transactivation of the epidermal growth factor receptor (EGFR), an effect that is independent of its antimicrobial activity (Tokumaru et al., 2005). This dual role — killing pathogens while simultaneously signaling tissue repair — is unusual among antimicrobial agents.

Practical Implications

The wound healing literature has translated into two phase II randomized controlled trials of topical LL-37:

A multicenter phase IIb RCT in venous leg ulcers reported no significant improvement in the full population, though a subgroup with large ulcers showed potential benefit (Mahlapuu et al., 2021)

A double-blind RCT of LL-37 cream in mildly infected diabetic foot ulcers reported enhanced healing rates (Miranda et al., 2023)

Reviews have proposed LL-37 as a candidate topical for polymicrobial infected wounds, combining anti-biofilm activity with wound-healing signaling.

Immune Modulation

Beyond direct pathogen killing, LL-37 functions as a sophisticated immunomodulator — acting as a bridge between innate and adaptive immunity.

Immune Cell Recruitment

LL-37 has been reported to act as a chemoattractant, recruiting immune cells to sites of infection or injury:

Neutrophils and monocytes: Reported recruitment via formyl peptide receptor signaling

T-cells: Reported chemotactic activity for CD4+ T-lymphocytes, linking innate antimicrobial defense to adaptive immunity

Mast cells: Reported activation with downstream histamine release

Cytokine and Inflammatory Modulation

LL-37 has a complex, context-dependent relationship with inflammation (Kahlenberg & Kaplan, 2013):

LPS neutralization: LL-37 has been reported to bind and neutralize bacterial lipopolysaccharide (LPS), dampening excessive TLR4-driven inflammation

TLR modulation: Modulates Toll-like receptor signaling, influencing the downstream inflammatory cascade

Dual role: Can both promote inflammation (recruiting immune cells, activating TLRs) and resolve it (neutralizing LPS, modulating cytokine profiles) depending on concentration and context

This dual nature is why LL-37 is described as an "immunomodulator" rather than simply "immunostimulatory" — it helps calibrate the immune response rather than just amplify it (Kahlenberg & Kaplan, 2013).

Dendritic Cell Activation

LL-37 enhances dendritic cell (DC) maturation and antigen presentation:

Promotes DC differentiation from monocytes

Enhances antigen uptake and presentation to T-cells

May improve vaccine responses by serving as a natural adjuvant

The Vitamin D Connection

The link between Vitamin D and LL-37 is one of the most significant discoveries in innate immunity research.

The Molecular Mechanism

In 2006, a landmark study in Science showed that Vitamin D directly induces LL-37 expression in macrophages and contributes to killing of intracellular Mycobacterium tuberculosis (Liu et al., 2006):

Toll-like receptor activation upregulates the Vitamin D receptor (VDR) and the 1-hydroxylase that converts 25(OH)D to active 1,25(OH)₂D

Active Vitamin D then binds the VDR, which activates the Vitamin D Response Element (VDRE) in the cathelicidin gene promoter

This triggers transcription and production of hCAP18, which is cleaved to release active LL-37

Clinical Significance

This Vitamin D-LL-37 axis has been used to explain several clinical observations:

Winter infection susceptibility: Lower Vitamin D levels in winter have been correlated with reduced LL-37 production and higher infection rates

Tuberculosis and Vitamin D: The historical use of sunlight/Vitamin D for TB treatment may work partly through cathelicidin induction, consistent with the TLR/vitamin D macrophage pathway (Liu et al., 2006)

COVID-19 and Vitamin D: The association between Vitamin D deficiency and worse COVID-19 outcomes has been hypothesized — though not proven — to be partially mediated by reduced LL-37 production

Practical Takeaway

Vitamin D status is described in the research as the most accessible lever on natural LL-37 production. This is why community protocols for exogenous LL-37 almost universally describe Vitamin D3 co-supplementation.

Potential Cancer Research

LL-37's role in cancer is an active and complex area of investigation. The relationship is not straightforward — LL-37 shows both anti-tumor and pro-tumor effects depending on cancer type.

Anti-Tumor Effects

Preclinical studies have reported LL-37-induced cancer cell death in several cancer types:

Gastric cancer: Reports of apoptosis induction in gastric cancer cell lines

Colon cancer: Reported antiproliferative effects in colon cancer cell lines

Hematologic cancers: Reports of apoptosis in leukemia and lymphoma cells via caspase-independent pathways

Ovarian cancer: Enhanced antitumor effects in preclinical models when LL-37 is combined with CpG oligodeoxynucleotides

The proposed selectivity for cancer cell membranes — which tend to carry more negative charge than normal cell membranes — is the basis for ongoing research into LL-37 fragments as candidate anticancer agents. All work to date is preclinical.

The Complexity

Important caveat: LL-37 has also been associated with promoting tumor growth in certain cancers, particularly breast, ovarian, and lung cancers, where it may promote angiogenesis and cell proliferation. This dual role makes blanket statements about LL-37 and cancer inappropriate and highlights the need for more research.

Gut Health Applications

LL-37's expression in intestinal epithelial cells makes it relevant to gastrointestinal health:

Intestinal Barrier Function

LL-37 has been reported to strengthen tight junctions between intestinal epithelial cells in cell-culture models, supporting gut barrier integrity

Preclinical work has linked LL-37 to enhanced intestinal epithelial wound healing in gut epithelial models

This barrier-protective effect is often cited in discussions of "leaky gut" and intestinal permeability, though clinical evidence is absent

Inflammatory Bowel Disease (IBD)

Altered cathelicidin expression has been observed in both Crohn's disease and ulcerative colitis patients

LL-37's combined antimicrobial and barrier-protective properties make it a subject of interest in IBD research

The peptide's ability to neutralize LPS may help reduce the inflammatory cascade triggered by bacterial translocation across a compromised gut barrier

Gut Microbiome Considerations

LL-37 may selectively target pathogenic bacteria while relatively sparing beneficial commensal organisms, though this selectivity is concentration-dependent

Its anti-biofilm properties could be relevant to gut biofilm-associated conditions